TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTIONS

Chaire Francqui - 3/04/2003

Click here to start

Table of Contents

TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTIONS

Transmission of Hepatitis B Infection

Natural History of Chronic HBV Infection

Global Distribution of Chronic HBV Infection

Metabolic pathway of 3TC (Lamivudine) and interaction with HIV and HBV DNA

HBV DNA Reduction versus Lamivudine Bioavailability

Antiviral activity of L-nucleoside analogues

Antiviral activity spectrum of PMEA (Adefovir) and PMPA (Tenofovir)

Mechanism of action of adefovir (PMEA)

Distribution of hepatitis B virus genotypes and key mutations in HBV polymerase

Incidence of lamivudine resistance in chronic hepatitis B

Adefovir dipivoxil in (lamivudine-resistant) hepatitis B patients – Study 461

Adefovir dipivoxil in (lamivudine-resistant) hepatitis B patients – Study 461 (continued)

Durability of efficacy of adefovir dipivoxil in hepatitis B patients

Adefovir dipivoxil in hepatitis B patients infected with different HBV genotypes

Author: E. De Clercq

Email: tulkens@facm.ucl.ac.be

Home Page: http://www.md.ucl.ac.be/chaire-francqui/slides

Other information:
These slides are for information only. Do not make public use of them without the autorization of Prof. E. De Clercq and the organizers of the "Chaire Francqui". Please, adress your request to <tulkens@facm.ucl.ac.be>

Download presentation source as PDF file (2.4 Mb)